Cytokinetics, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Cytokinetics, Inc. has filed its 2023 annual report (10-K) detailing its business operations, financial status, and key agreements.</b>

AI Summary

CYTOKINETICS INC (CYTK) filed a Annual Report (10-K) with the SEC on February 28, 2024. Cytokinetics, Inc. filed its 2023 Form 10-K on February 28, 2024. The company is in the Pharmaceutical Preparations industry (SIC 2834). Key agreements mentioned include the JiXing Omecamtiv Mecarbil License and Collaboration Agreement and the JiXing Aficamten License and Collaboration Agreement. Financial instruments and agreements such as Term Loan Agreements and Royalty Purchase Finance Trust Agreements are referenced. The filing covers fiscal year ending December 31, 2023.

Why It Matters

For investors and stakeholders tracking CYTOKINETICS INC, this filing contains several important signals. This 10-K filing provides a comprehensive overview of Cytokinetics' business, including its product pipeline, strategic partnerships, and financial performance for the fiscal year 2023. Investors and stakeholders can use this report to assess the company's progress, risks, and future outlook, particularly concerning its pharmaceutical development and licensing activities.

Risk Assessment

Risk Level: medium — CYTOKINETICS INC shows moderate risk based on this filing. The company operates in the highly regulated pharmaceutical industry, facing risks related to drug development, clinical trials, regulatory approvals, and market competition, as evidenced by the numerous agreements and product development milestones mentioned.

Analyst Insight

Review the detailed financial statements and risk factors in the 10-K to understand Cytokinetics' financial health and the specific challenges it faces in drug development and commercialization.

Key Numbers

• 2023-12-31 — Fiscal Year End (Conformed period of report)
• 2024-02-28 — Filing Date (Filed as of date)
• 2834 — Standard Industrial Classification (Pharmaceutical Preparations)
• 000-50633 — SEC File Number (SEC file number)

Key Players & Entities

• CYTOKINETICS INC (company) — Filer name
• 350 OYSTER POINT BOULEVARD (location) — Business and mailing address
• SOUTH SAN FRANCISCO (location) — City for business and mailing address
• CA (location) — State for business and mailing address
• 94080 (location) — ZIP code for business and mailing address
• JiXing Omecamtiv Mecarbil License and Collaboration Agreement (agreement) — Specific license and collaboration agreement
• JiXing Aficamten License and Collaboration Agreement (agreement) — Specific license and collaboration agreement
• Amgen (company) — Mentioned in relation to revenue

FAQ

Risk Factors

• Regulatory Risks [high — regulatory]: The company faces significant risks related to the lengthy and complex process of obtaining regulatory approval for its drug candidates, including potential delays or failures in clinical trials and regulatory reviews.
• Market Competition [high — market]: The pharmaceutical market is highly competitive, with numerous companies developing therapies for similar conditions, posing a risk to Cytokinetics' market share and commercial success.
• Financing and Liquidity [medium — financial]: As a development-stage biopharmaceutical company, Cytokinetics may require substantial additional funding to support its ongoing research, development, and commercialization activities, posing liquidity risks.
• Reliance on Key Personnel and Third Parties [medium — operational]: The company's success depends on its ability to attract and retain key scientific and management personnel, as well as its reliance on third-party manufacturers and collaborators.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K filing.

Key Financial Figures

• $0.001 — : Title of each class Common Stock, $0.001 par value Trading symbol CYTK Nam

Filing Documents

• cytk-20231231.htm (10-K) — 3486KB
• cytk-ex10_6.htm (EX-10.6) — 76KB
• cytk-ex23_1.htm (EX-23.1) — 7KB
• cytk-ex31_1.htm (EX-31.1) — 15KB
• cytk-ex31_2.htm (EX-31.2) — 14KB
• cytk-ex32_1.htm (EX-32.1) — 12KB
• cytk-ex97_1.htm (EX-97.1) — 48KB
• img257646110_0.jpg (GRAPHIC) — 34KB
• 0000950170-24-022256.txt (&nbsp;) — 12695KB
• cytk-20231231.xsd (EX-101.SCH) — 1776KB
• cytk-20231231_htm.xml (XML) — 2091KB

Forward Looking Statements Private Securities Litigation Reform Act of 1995

Forward Looking Statements Private Securities Litigation Reform Act of 1995 7 Summary of Principal Risk Factors 9 PART I Item 1.

Business

Business 11 Item 1A.

Risk Factors

Risk Factors 30 Item 1B. Unresolved Staff Comments 60 Item 1C. Cybersecurity 60 Item 2.

Properties

Properties 62 Item 3.

Legal Proceedings

Legal Proceedings 62 Item 4. Mine Safety Disclosures 62 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 63 Item 6. [Reserved] 64 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 65 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 74 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 75 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 106 Item 9A.

Controls and Procedures

Controls and Procedures 106 Item 9B. Other Information 108 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 108 PART III Item 10. Directors, Executive Officers and Corporate Governance 109 Item 11.

Executive Compensation

Executive Compensation 109 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 109 Item 13. Certain Relationships and Related Transactions, and Director Independence 109 Item 14. Principal Accountant Fees and Services 109 PART IV Item 15. Exhibits and Financial Statement Schedules 110 Exhibits 110 Item 16. Form 10-K Summary 114

Signatures

Signatures 115 Table of Contents Glossary of Terms Unless the context requires otherwise, references to "Cytokinetics," "the Company," "we," "us" or "our" in this Form 10-K (defined below) refer to Cytokinetics, Incorporated and its subsidiaries. References to "Notes" in this Form 10-K are to the Notes to the Consolidated Financial Statements in this Form 10-K. We also have used other specific terms in this Form 10-K, most of which are explained or defined below: Term/Abbreviation Definition 2004 Plan Cytokinetics' Amended and Restated 2004 Equity Incentive Plan 2020 RTW Transactions The transactions contemplated by the RTW Royalty Purchase Agreement, Ji Xing Aficamten License Agreement and the Common Stock Purchase Agreements, dated July 14, 2020, by and between Cytokinetics and the RTW Investors 2021 RTW Transactions The transactions contemplated by the Ji Xing OM License Agreement and the Common Stock Purchase Agreements, dated December 20, 2021 by and between Cytokinetics and the RTW Investors 2022 RPI Transactions The transactions contemplated by the RP Loan Agreement and the RP Aficamten RPA 2026 Notes Cytokinetics' 4% convertible senior notes due 2026 2027 Indenture Indenture Agreement, dated July 6, 2022, between Cytokinetics and U.S. Bank Trust Company, as trustee 2027 Notes Cytokinetics' 3.50% convertible senior notes due 2027 ACA Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act ACACIA-HCM Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM ACC American College of Cardiology AHA American Heart Association ALS amyotrophic lateral sclerosis (also known as Lou Gehrig's Disease) ALSFRS-R ALS Functional Rating Scale – Revised Amended ATM Facility amended and restated Controlled Equity Offering Sales Agreement Amgen Agreement Collaboration and Option Agreement, dated December 29, 2006, as

View Full Filing

View this 10-K filing on SEC EDGAR